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STABILITY OF MARKERS USED FOR REAL-TIME TUMOR TRACKING AFTER
PERCUTANEOUS INTRAPULMONARY PLACEMENT
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E-mail: nPurpose: To determine the stability of markers used for real-time tumor tracking after percutaneous intrapulmo-
nary placement.
Methods and Materials: A total of 42 patients with 44 lesions, 111 markers, and$2 repeat computed tomography
(CT) scans were studied. The tumor on the repeat CT scans was registered with the tumor on the planning CT scan.
Next, the three-dimensional marker coordinates were determined on the planning CT scan and repeat CT scans.
Marker stability was analyzed by the displacement of the markers and the displacement of the center of mass
(COM) of the marker configurations. In addition, we assessed the reliability of using the intermarker distance
as a check for displacements in the COM of the marker configurations.
Results: The median marker displacement was 1.3 mm (range, 0.1–53.6). The marker displacement was >5 mm in
12% of the markers and >10 mm in 5% of the markers. The causes of marker displacement >5 mm included
marker migration (2 of 13) and target volume changes (5 of 13). Nonsynchronous tumor and marker movement
during breathing might have been responsible for the displacements >5 mm in the other 6 of 13 markers. The me-
dian displacement in the COM of the marker configurations was 1.0 mm (range, 0.1–23.3). Displacements in the
COM of the marker configurations of$2.0 mm were detected by changes in the intermarker distance of >1.5 mm
in 96% of the treatment fractions.
Conclusion: The median marker displacement was small (1.3 mm). Nevertheless, displacements >5 mm occurred
in 12% of the markers. Therefore, we recommend the implantation of multiple markers because multiple markers
will enable a quick and reliable check of marker displacement by determining the change in the intermarker dis-
tance. A displacement in the COM of the marker configuration of$2.0 mm was almost always detected (96%) by
a change in the distance between the markers of >1.5 mm. This enabled the displaced marker to be disabled, such
that tumor localization was not compromised.
 2011 Elsevier Inc.
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INTRODUCTION
Stereotactic radiotherapy delivers escalated doses to the tu-
mor using tight margins and a highly conformal dose distri-
bution. As such, accurate tumor localization is required to
prevent underdosage of the tumor or overdosage of the or-
gans at risk. Several approaches can be used to localize the
tumor during stereotactic radiotherapy. These approaches
have included the use of cone-beam computed tomography
imaging, electronic portal imaging, and stereoscopic kilo-
voltage x-ray imaging. Because electronic portal imaging
and stereoscopic kilovoltage x-ray imaging rarely allowmor localization, a surrogate is often required to
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e75determine the three-dimensional tumor location. Surrogates
such as the bony anatomy or the position of anatomic land-
marks (carina/diaphragm) can be used, depending on the tu-
mor site and location. The use of these surrogates to
determine the tumor position can, however, be inaccurate
due to intrafraction and interfraction variations in the rela-
tionship between the surrogate structures and the tumor
(1). A more direct method to detect the tumor position would
be the use of markers implanted in or near the tumor.
At our institute, implanted markers are often used as a sur-
rogate for the position of early-stage non–small-cell lungtumors during CyberKnife stereotactic radiotherapy. To
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the implanted markers remains stable relative to the tumor
position. Concerns regarding tumor localization using im-
planted markers are that markers may migrate from their ini-
tial position or that the surrounding tissues may swell or
deform during treatment.
Two studies have previously examined the stability of im-
plantedmarkers during treatment. The first study assessed the
stability of 1.5-mmgoldmarkers implanted via bronchoscopy
in 11 patients (2). These 11 patients were selected from a total
of 57 patients and did not include those patients in whom the
markers had been displaced after bronchoscopybut before the
first fraction of radiotherapy. The second study examined the
stability of a 2.0-cm-longmarker placed in the lung tumor us-
ing bronchoscopy in 8 patients and using the percutaneous in-
trapulmonary approach in 15 patients (3). Similar to the
second study, we also placed markers using the percutaneous
intrapulmonary approach. However, we used a smaller
4.0-mm-long platinum marker and multiple markers were
placed for most of the tumors. The toxicity related to percuta-
neous implantation of the 4.0-mm platinummarkers has been
previously reported (4, 5). The aim of the present studywas to
determine the stability of the 4.0-mm platinum markers
placed using the percutaneous intrapulmonary approach in
42 patients. In addition, we assessed whether a change in
the distance between markers was a reliable check of the
displacement of the center of mass (COM) of the marker
configuration relative to the tumor.METHODS AND MATERIALS
Patient selection and marker placement
Patients were included in the present study if markers had been
placed using the percutaneous intrapulmonary approach. Percuta-
neous intrapulmonary marker placement was performed under lo-
cal anesthesia by an experienced radiation oncologist or an
intervention radiologist. An 18-gauge needle was used to place
markers in or near the tumor using fluoroscopic, computed tomog-
raphy (CT), or ultrasound guidance. Ideally, three platinummarkers
were placed. The smooth markers were 4.0 mm long and had a di-
ameter of 0.9 mm. The markers were manufactured in house using
platinum thread delivered by Drijfhout (Amsterdam, The Nether-
lands). As percutaneous marker placement can be complicated by
a pneumothorax or hemorrhage, two anteroposterior chest radio-
graphs were taken, one directly after the procedure and the second
1 hour later.
Approximately 1 week after marker placement, an exhale breath-
hold treatment planning CT scan was made. The planning CT scan
had a slice thickness and spacing of 1.5–2.0 mm. Details concerning
treatment planning have been described previously (6). Briefly, the
gross tumor volume (GTV) was contoured using lung window. The
planning target volume was equal to the GTV plus 5 mm. Patients
with peripheral tumors were treated with 3  20 Gy. Patients with
central tumors (7) were treated with 6  8 Gy, if the tumor was
located near the esophagus, or 5 12Gy for all other central tumors.Registration of repeat CT scans
During the treatment course, repeat CT scans were made using
the same settings as for the planning CT scan (exhale breath-hold). The repeat CT scans were made before each treatment
fraction for patients with peripheral tumors (repeat CT-1, CT-2,
and CT-3) and before the first, third, and last treatment fraction (re-
peat CT-1, CT-2, and CT-3) for patients with central tumors. For the
purposes of the present study, we registered the tumor on the repeat
CT scans to the tumor on the planning CT scan. A two-step ap-
proach was used for registration. First, automated registration
was performed on a region of interest, including the GTV and
a minimal volume of the surrounding normal lung tissue. The
cost function of the registration used the root-mean-square differ-
ence in Gray values as a metric. The registration included both
translations and rotations (Fig. 1). The second step involved a visual
check of each registration using the reference structures in or near
the tumor (bronchial trees or pulmonary vessels). These reference
structures were used to adjust the registration if the automated reg-
istration could be improved. The uncertainty related to the registra-
tion of the CT scans was expected to be approximately 0.75–1.0
mm because the CT slice spacing was 1.5–2 mm. Once the CT
images had been registered, we determined the three-dimensional
coordinate of each marker on the planning CT scan and the corre-
sponding marker coordinate on the repeat CT scans.Marker stability assessment
Marker stability was first assessed by the displacement of the in-
dividual markers. The displacement of an individual marker was
defined by the vector connecting the marker coordinate on the plan-
ning CT scan and the corresponding marker coordinate on the re-
peat CT scan. The marker coordinate was determined at the
center of each marker. If the individual markers were displaced
by >5.0 mm, we visually inspected the CT registrations to deter-
mine the cause of marker displacement. Marker displacement
was compared for markers placed in the tumor vs. outside the tumor
and for markers of central tumors vs. peripheral tumors. We also
evaluated whether marker displacement was affected by the
interval between the planning CT scan and the repeat CT scan.
Next, the marker stability was assessed by the displacement of the
COM of the marker configuration. This was done because Cyber-
Knife tumor localization is based on the COM of the marker config-
uration. First, the COM of the marker configuration was determined
on the planning CT scan and on the repeat CT scans by calculating
the average of the individual marker coordinates on these CT scans.
Next, the displacement of the COM coordinates of the marker con-
figuration was determined by calculating the vector between the
COM coordinates on the planning CT scan and the repeat CT scan.
Finally, we assessed whether a change in the distance between
the markers could reliably detect a displacement of the marker con-
figuration relative to the tumor position. Patients with at least two
markers were included in this analysis. As a quality assurance
check, the CyberKnife tumor tracking system generates a warning
if the distance between the markers has deviated by >1.5 mm from
the reference configuration on the planning CT scan. This warning
allows the physician to identify and disable the displaced marker or
to increase the tolerated deviation from 1.5 mm to a maximum of
5.0 mm. We determined whether a relevant displacement in the
COM of the marker configuration ($2.0 mm) was accompanied
by a change in the distance between the markers of >1.5 mm. A dis-
placement in the COM of the marker configuration of $2.0 mm
was considered relevant. This value ($2.0 mm) was chosen to
account for the uncertainty related to the registration of the CT
scans. Marker COM displacements of $2.0 mm were also consid-
ered clinically relevant, because 2 mm has been used for other un-
certainties such as the respiratory tumor tracking uncertainty
Fig. 1. (a) Registration of the planning computed tomography (CT) scan and the repeat CT scan. Markers are represented
by black dots on the planning CT scan and by open squares on the repeat CT scan. The center of mass of marker config-
uration is indicated by ‘‘X’’ on planning CT scan and ‘‘X0’’ on the repeat CT scan. (Appendix)
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tumor tracking error was 1.2 mm (vector of the mean correlation
model error) (8).
Statistical analysis
Multilevel mixed-effects linear regression analysis was used to
evaluate the association between marker displacement and (1) the
location of the marker (inside vs. outside the tumor), (2) the loca-
tion of the tumor (peripheral vs. central), and (3) the interval
between the repeat CT scan and the planning CT scan. All p values
are two sided, and a significance level of a = 0.05 was used.
RESULTS
Patient selection
Of the 42 patients, 38 patients with 40 tumors underwent
three repeat CT scans and 4 patients with four tumors under-
went two repeat CT scans. The average interval between
marker placement and the planning CT scan was 9  4
days (range, 3–26). The average interval between the plan-
ning CT scan and the repeat CT scan was 8  3 days for
CT-1, 11  3 days for CT-2, and 14  4 days for CT-3. A
total of 111 markers were placed, and 80% of the tumors
(35 of 44) had two or more markers placed either in or
near the tumor. None of the implanted markers were
coughed up between implantation and the planning CT
scan. The patient, tumor, and marker characteristics are
listed in Table 1.
Registration of repeat CT scans
The average rotational adjustment during automatic regis-
tration was 0.2  3 (range, 11–16). In 4 of the 44 tu-
mors, manual adjustments were made after the automated
registration of one or more of the repeat CT scans. These
adjustments were made because of changes in the tumor
volume or shape.
Marker stability
Themedian displacement of markers was 1.1 mm on CT-1
(range, 0.2–20.7), 1.2mm on CT-2 (range, 0.1–25.4), and 1.3
mm on CT-3 (range, 0.3–53.6; Fig. 2). The displacement of
markers along any anatomic axis is given in Table 2. Marker
displacement exceeded 5 mm in 13 of 111 markers (12%)placed in 9 patients. Marker displacement exceeded 10
mm in 5 of 111 makers (4%) placed in four patients. These
markers were displaced by more than 5 or 10 mm in one or
more repeat CT scans.
On visual inspection of the CT registration, the cause of
marker displacement >5 mm was marker migration (2 of
111 markers; 2%), tumor regression (4 of 111 markers;
4%), tumor deformation (1 of 111 markers; 1%) and possi-
bly nonsynchronous tumor-marker motion (6 of 111
markers; 5%). Two markers had migrated relative to the tu-
mor and the surrounding structures in one patient. Four
markers placed in three tumors were displaced because of tu-
mor regression. Finally, one marker was displaced because
of tumor deformation (this tumor had changed shape without
a visually evident regression in the tumor volume). For the
remaining six markers, a clear cause of marker displacement
>5 mm could not be identified. For five of these markers, the
CT registration showed an accurate tumor match but also
a slight respiratory phase difference (difference in the posi-
tion of the ribs, diaphragm, and vertebra). These markers
might have moved nonsynchronously to the tumor. The
five markers were all placed furthest from the tumor com-
pared with the other implanted markers (Table 3). For the
sixth marker, a respiratory phase difference was not evident
between the planning CT scan and repeat CT scan. However,
we did observe a pulmonary infiltrate on the repeat CT scan,
which might have influenced the motion of the marker but
not that of the tumor.
Marker position (in or near the tumor) and tumor location
(peripheral/central) did not significantly influence the inci-
dence of marker displacement. An increase in the interval
between the planning and repeat CT scan significantly in-
creased the displacement of markers (p < .01). The magni-
tude of this effect was small (0.30 mm/d, 95% confidence
interval, 0.21–0.38 mm/d).
The median displacement of the COM of the marker
configurations was similar to the median displacement of
the individual markers (1.0 mm on all three CT scans vs.
1.1–1.3 mm). However, the maximal displacement of the
COM of the marker configurations was much smaller than
the maximal displacement of the individual markers (7.4
mm vs. 20.7 mm on CT-1, 8.2 mm vs. 21.0 mm on CT-2,
Table 2. Displacement of individual markers on repeat
computed tomography scans
Axis
Repeat CT-1
(mm)
Repeat CT-2
(mm)
Repeat CT-3
mm)
Left–right
Average 0.1 0 0.1
SD 1.9 2.2 3.2
Range 15.9–3.9 20.1–4.5 28.2–8.6
Craniocaudal
Average 0.3 0.2 0.4
SD 1.9 2.2 3.2
Range 13.1–3.8 14.8–6.3 22.7–4.5
Anteroposterior
Average 0 0.5 0.2
SD 1.3 1.6 4.4
Range 4.6–3.6 3.0–7.2 41.7–5.8
Average 3D
distance*
1.9  2.6 2.0  3.1 2.8  5.8
Abbreviations: SD = standard deviation; 3D = three-dimen-
sional.
* Data presented as average  SD.
Table 1. Patient and tumor characteristics
Characteristic Value
Gender (n)
Male 32
Female 10
Tumor size (cm)
Mean 4.2
Range 1.0–10.5
Tumor location (n)
Right upper lobe 11 (25)
Right middle lobe 5 (11)
Right lower lobe 9 (20)
Left upper lobe 13 (30)
Left lower lobe 6 (14)
Peripheral tumor location (n) 31 (70)
Central tumor location (n) 13 (30)
Markers detected on planning CT scan (n) 111 (100)
Markers per tumor (n)
1 9 (21)
2 10 (23)
3 18 (41)
4 7 (16)
Marker location (n)
Inside tumor 58 (52)
Outside tumor 53 (48)
Data in parentheses are percentages.
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marker configurations was displaced by >5mm in 3 of the 44
marker configurations (7%). These marker configurations
were displaced by >5 mm in only one CT registration (n =
2) or all three CT registrations (n = 1). The COM of one
marker configuration was displaced by >10 mm on one re-
peat CT scan.
A total of 34 patients with 35 tumors had at least two
markers placed and were included in the following analysis:
‘‘Is the change in the distance between markers a reliable
check for displacements in the COM of the marker configu-
ration relative to the tumor position?’’ A total of 102 CT scan
registrations were available, because 31 patients with 32
tumors had undergone 3 repeat CT scans (n = 96) and 3
patients with 3 tumors had had 2 repeat CT scans (n = 6).Fig. 2. Displacement of individual markers on repeat computed to-
mography scans.A displacement in the COM of the marker configuration of
$2.0 mm was accompanied by a detectable change in the
distance between markers of >1.5 mm in all but 4% of the
CT registrations (4 of 102). A displacement of the COM of
the marker configuration of $3.0 mm was accompanied
by a detectable change in the distance between the markers
of >1.5 mm in all but 1% of the CT registrations (1 of 102;
Fig. 4). In one CT registration, the change in the COM of
the marker configuration was large (7 mm), but the change
in the distance between the markers was only 2 mm
(Fig. 4). Despite this, an error in tumor targeting did not oc-
cur. The marker configuration was a mirror image of the
original configuration; thus, the CyberKnife system could
not recognize the original marker configuration on the ste-
reoscopic x-ray images.DISCUSSION
Our results have shown that the median displacement of
markers placed using the percutaneous intrapulmonary ap-
proach is 1.3 mm during treatment. However, marker dis-
placements >5 mm occurred in 12% of the markers (13 of
111). Visual inspection revealed that displacements >5 mm
did not necessarily reflect marker migration.
Large marker displacements were also caused by tumor
regression/deformation and, perhaps, by nonsynchronous tu-
mor–marker motion. Although lung tumors frequently re-
gress during conventional radiotherapy (9, 10), previous
stereotactic radiotherapy studies merely observed slow
tumor regression (11, 12). In our study, only a few of the
tumors significantly changed in volume or shape (4 of 44;
9%). In these tumors, the short onset of regression was
perhaps related to tumor-specific characteristics and/or the
delivery of three to five high fraction doses within 1 week.
None of the reductions in tumor volume were related to
the disappearance of atelectasis. In addition to tumor
Table 3. Causes of marker displacement according to visual inspection of CT registration
Pt. No. Marker (location) Displacement (mm) Cause Dmarker (mm) Tumor diameter (mm) Tumor pathologic type*
1 1 (O) 5.3 Uncertainy 83.7 32.0 No pathology available
2 2 (O) 5.3 Uncertainy 36.1 32.0 Adenocarcinoma
3 3 (O) 6.1 Uncertainy 27.3 27.0 Large cell
4 4 (O) 9.3 Uncertainy 30.0 25.0 No pathology available
4 5 (O) 6.8 Uncertainy 31.2 25.0 No pathology available
5 6 (O) 12.5 Uncertainy 37.3 69.0 No pathology available
5 7 (I) 5.3 Tumor regression 26.0 69.0 No pathology available
6 8 (I) 10.4 Tumor regression 36.8 100.5 Large cell
6 9 (I) 8.1 Tumor regression 35.0 100.5 Large cell
7 10 (I) 10.9 Tumor regression 29.6 63.0 None
8 11 (O) 6.1 Tumor deformation 32.7 83.0 Squamous cell
9 12 (I) 53.6 Migration 9.5 63.0 Squamous cell
9 13 (I) 23.8 Migration 6.2 63.0 Squamous cell
Abbreviations: Pt. No. = patient number; Dmarker = distance between center of marker and center of tumor; O = outside tumor; I = inside
tumor.
* For makers displaced by <5 mm, the tumor pathology was: squamous cell carcinoma (17%), adenocarcinoma (27%), large cell carcinoma
(29%), other (7%), and no pathology available (20%).
y Cause might have been nonsynchronous tumor–marker motion.
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have been caused by nonsynchronous tumor-marker move-
ment. In 6 of 13 markers, a definite cause of marker displace-
ment >5 mm could not be identified. These six markers
might have migrated. A plausible alternative is that these
markers moved nonsynchronously to the tumor. The six
markers were the markers most distal from the tumors
(2.7–8.4 cm away from the tumor center). As such, the
risk of nonsynchronous tumor–marker motion might be re-
lated to the distance between the marker and tumor. How-
ever, additional research using four-dimensional
respiratory-correlated CT scans is required to (1) determine
the extent of nonsynchronous tumor–marker motion during
respiration, and (2) assess whether a greater tumor–marker
distance increases the risk of nonsynchronous tumor–marker
motion.
Because large marker displacements can occur, a reliable
check for marker displacement is required to reduce the risk
of inaccurate tumor localization. The CyberKnife real-time
tumor tracking system localizes the tumor using the COMFig. 3. Displacement in the center of mass of marker configura-
tions on repeat computed tomography scans.of the marker configuration. Large COM displacements
were observed in some fractions (#23.3 mm; median,
1.0). Therefore, we recommend a reliable check for dis-
placements in the marker configuration COM before each
treatment fraction. Our results have shown that the change
in the distance between markers is a reliable check of the dis-
placements in the COM of the marker configuration relative
to the tumor position. Displacements in the COM of the
marker configuration of $2.0 mm were almost always ac-
companied by a change in the distance between markers of
>1.5 mm. Because the CyberKnife tumor tracking system
generates a warning if the distance betweenmarkers deviates
by >1.5 mm from the reference configuration, marker con-
figuration COM displacements of$2.0 mm will be detected
in the majority of cases. Thus, the displaced markers can be
identified and the tumor can be localized using the remaining
stable markers. Displacements of <2.0 mm can be accountedFig. 4. Change in center of mass (COM) of marker configurations
and the corresponding maximum change in intermarker distance
(IMD). Changes in marker configuration COM of $2 mm were
considered relevant (above the gray-shaded area). Open circles rep-
resent undetected changes in the COM; solid circles represent de-
tected changes.
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creasing the margin such that for all or nearly all patients
the tumor will be covered adequately even with the occur-
rence of large marker migration. Instead, it is our policy to
disable the displaced marker.
A previous study reported the fixation rate of 1.5-mm gold
markers after bronchoscopic placement in 57 patients with
peripheral lung cancer (2). Of the 154 implanted markers,
122 (79%) could be detected at treatment planning com-
pared with 100% in our study (Table 1). The rate of marker
fixation was greater for peripheral tumors than for central tu-
mors. Imura et al. (2) hypothesized that the rate of marker
fixation depended on the diameter of the marker in relation
to the bronchus. Perhaps the fixation rate was greater in
our study because larger markers (4.0 mm vs. 1.5 mm)
were used in mostly peripheral tumors (smaller bronchi di-
ameter). Imura et al. (2) also studied the stability of markers
during treatment in 11 of 57 patients. The change in the dis-
tance between markers was much smaller than in our study
(#2.0 mm in 95% of cases vs. #6.2 mm in 95% of cases).
However, the analysis did not include those patients in
whom a marker had migrated after treatment planning
(7 of 122 markers; 6%). In addition, the stability of the
markers during treatment was assessed in a small number
of patients (n = 11). The number of markers placed in these
11 patients was not reported (2).
The average displacement of the markers used in our
study was similar to the displacement of a 2.0-cm-long
marker placed in lung tumors using the percutaneous intra-
pulmonary approach (n = 15 markers) or the bronchoscopic
approach (n = 8 markers) (3). The average displacement of
the 2.0-cm-long marker was 2.6 mm vs. 2.8 mm in our study.
However, the maximal displacement was much lower than in
our study (5.4 mm vs. 53.6 mm). The investigators stated
that marker displacements >5.4 mm were probably not ob-
served because the 2.0-cm-long markers were more likely
to get wedged in the lung than were smaller markers. We
clearly observed migration in two markers and, possibly,
in another six markers, for which the cause of displacement
was unclear (2–8 of 111 markers). Although the 4.0-mm
markers used in our study might be more susceptible to mi-
gration than the 2.0-cm-long markers, this cannot be con-
cluded solely from the present results. In our study,
nonsynchronous tumor–marker motion might have caused
displacements of $5 mm in six markers. Nonsynchronous
tumor–marker motion was probably not an issue for the
2.0-cm-long markers because such markers were placed
into or directly bordering the tumor. In addition, the sample
size for the 2.0-cm-long marker study was much smaller
than our sample size (23 vs. 111 markers). Thus, the lower
migration rate for the 2.0-cm-long marker might have been
coincidental.
It has been debated whether a single or multiple markers
should be used for stereoscopic x-ray–guided radiotherapy
(13). From our results, we recommend the use of multiple
markers. An advantage of using multiple markers is that
marker displacements can be easily detected on the stereo-scopic x-ray images through changes in the marker configu-
ration. This would not be possible if a single marker were
used. Displacements of a single marker can remain unde-
tected and cause systematic localization errors. Some might
argue that large marker displacements are rare. However, we
observed displacements >5 mm in 12% of the markers. The
incidence of maker displacement might have been high in
our study owing to nonsynchronous tumor–marker motion
(because some of the markers were located >2 cm from
the tumor). Despite this, the largest displacements occurred
when the markers were placed inside the tumor. These dis-
placements were also observed more than1 week after im-
plantation; the interval considered sufficient for fixation/
fibrosis of the marker. Implantation of multiple markers
will also enable the detection of changes in tumor volume
and shape. Although tumor volume and shape changes will
be less relevant in small lung tumors, it is possible to adapt
the treatment plan in those cases in which large target vol-
ume changes have occurred. An argument against the use
of multiple markers is the greater risk of a pneumothorax
when multiple markers have been implanted. The risk of
pneumothorax after marker placement is not negligible
(range, 17–53%) (3–5). However, the development of
transbronchial, transesophageal, and vascular marker
placement techniques has reduced the risk of
pneumothorax (14–16). In the absence of these alternative
techniques, one should consider, per patient, whether the
greater risk of pneumothorax justifies the use of multiple
markers. If this risk is unacceptable, four-dimensional respi-
ratory-correlated CT scans should be made before each
treatment fraction to ensure that the single marker has re-
mained stable relative to the tumor. At our institute, vascular
embolization coils have frequently been used to mark the tu-
mor (intravascular approach). An interesting question is
whether marker displacement depends on the implantation
technique. Although we have not yet examined this, emboli-
zation coils placed using the intravascular approach will
probably be more stable than markers placed using the per-
cutaneous approach. These coils have been used extensively
in neurosurgical clipping of aneurysms, and migration of the
endovascular coils has not been described (17).
One limitation of our study was the accuracy of the CT
registration and the localization of the markers. In our study,
the CT scan slice spacing was 1.5–2.0 mm. Therefore, the
uncertainty in the CT measurement was, at best, 0.75–1.0
mm. Thus, the actual displacement of the individual markers
might have been smaller than the median displacement of
1.3 mm stated in our ‘‘Results’’ section.CONCLUSION
Intrapulmonary markers are generally stable as the me-
dian marker displacement was small (1.3 mm). However,
marker displacements >5 mm occurred in 12% of the
markers. Therefore, we recommend the implantation of mul-
tiple markers because this will enable a quick and reliable
check for marker displacement by determining the change
Stability of markers used for lung tumor tracking d N. C. VAN DER VOORT VAN ZYP et al. e81in the intermarker distance. A displacement in the COM of
the marker configuration of $2.0 mm was detected by
a change in the distance between the markers of >1.5 mmin 96% of the cases. This enabled the displaced marker to
be disabled such that tumor localization was not compro-
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